Hey @mirri11 , let me start by saying I'm no expert either ! Just reading what I can to understand, as is everyone else, but it is a complex beast.
This is how I understand it.
Basically, CDX has 3 ways to make money when selling to a doctor ( as opposed to clinical trials - different revenue stream)
1) The margin we make on selling the PULSE device ( and there are several models on who we sell the device to : distributor/wholesalers/direct to physician).
2) SaaS revenue. The app supplied by CDX for use by clinicians. It accumulates that data, helps with generating client reports, and most importantly, helps automate/streamline the reimbursement process.
3) Leasing model. Actually replaces 1) above. The clinical would get the client to lease the Pulse, rather than buy outright. The client may pay $50 a month to lease for 3 months ( by which time ongoing measurement may not be required). CDX were looking at a revenue sharing model here, where we own the device, and share in the leasing revenue.
As far as the reimbursement goes, that is between the clinician, patient and payor. But it does make using the PULSE far more attractive to the clinician, as they are going to make more $'s.
Best refer to the Conneqt Health website : https://conneqthealth.com/reimbursement/
A final thought on this.
I found it really interesting how the new president of CONNEQT HEALTH, Josh Stevens, presents his position on his LInkedIn profile.
"Provider & Payer Strategy & GTM"
It says to me that this exact question is his area of expertise, and one of the main reasons Craig has him on board.
How to sort through the Go to Market for PULSE and BAND such to maximise the return for shareholders.
Add to My Watchlist
What is My Watchlist?
